Background: Chemotherapy triggers endoplasmic reticulum (ER) stress, which in turn regulates levels of the active (LAP) and the natural dominant-negative (LIP) forms of the transcription factor C/EBP-β. LAP upregulates and LIP downregulates the multidrug resistance (MDR) protein P-glycoprotein (Pgp), but it is not known how critical is their role in establishing MDR.
Rapidly growing solid tumors are characterized by lagging angiogenesis, leading to hypoxia, nutrient deprivation, and accumulation of toxic metabolites. These pathophysiological conditions trigger endoplasmic reticulum (ER) stress (1) . The ability of tumor cells to resist stress is a hallmark of aggressive cancers (2, 3) . The cellular response to ER stress is termed the unfolded protein response (UPR). During early UPR, cells adapt to stress (1) . If ER stress persists, proapoptotic proteins such as CHOP (GADD153) and TRB3 are induced (4) . Despite different modes of action, many chemotherapeutic drugs-eg, anthracyclines (5), cisplatin (6) , oxaliplatin (5), 5-fluorouracil (7), paclitaxel (8)-share the ability to trigger ER stress (9) . Interestingly, chemotherapy efficacy is associated with increased ER stress (10, 11) . Hence, activation of the ER-dependent cell death machinery mediates part of the antiproliferative activity of numerous chemotherapeutic agents.
The frequently observed constitutive or drug-induced multidrug resistance (MDR) is often established by overexpression of integral membrane ATP binding cassette (ABC) drug efflux transporters, such as P-glycoprotein (Pgp/ABCB1), MDR-related In Vivo Tumor Growth 1 x 10 5 JC TetON LIP cells in 20 µl culture medium mixed with 20 µl Cultrex BME (Trevigen, Gaithersburg, MD) were orthotopically implanted according to (23) in six-week-old female BALB/c mice (15/group). The Institutional Animal Care and Use Committee of the Weizmann Institute of Science approved all animal protocols. Please see the Supplementary Methods (available online) for more details.
Statistical Analysis
All data in the text and figures are provided as means ± SD. The results were analyzed by two-sided analysis of variance (ANOVA). A P value of less than .05 was considered statistically significant.
Results

The Role of MDR in Resistance to ER Stress
We analyzed the response to chemotherapeutic agents and ER stress inducers in the human chemosensitive HT29 and A549 cells, in the chemoresistant counterpart (HT29/MDR and A549/MDR cells), in the constitutively chemoresistant murine JC cells and in human Caco-2 cells. HT29 cells basally express Pgp, MRP1, MRP2, and MRP3; A549 cells basally express MRP1, in line with the pattern of ABC transporters physiologically present in colon and lung mucosa (13) . HT29/MDR and A549/MDR cells express higher levels of these transporters and also express MRP5 and BCRP. JC cells constitutively express Pgp and low levels of BCRP; Caco-2 cells constitutively express Pgp, MRP1, and MRP2 (Supplementary Figure 1 , available online).
As expected, viability of HT29/MDR cells was higher than HT29 cells after exposure to irinotecan, a substrate of Pgp (24), 5-fluorouracil, whose resistance has been associated with Pgp, MRP1 and MRP5 (25) (26) (27) , and oxaliplatin, whose resistance has been associated with Pgp, MRP1, and MRP4 (survival of HT29/ MDR vs HT29 cells: P = .04 for the lowest dose of each drug, P = .03 for the intermediate and highest doses) ( Figure 1A , upper panels) (28, 29) . HT29/MDR cells were also more resistant to ER stress inducers, including thapsigargin, tunicamycin, and brefeldin A ( Figure 1A , lower panels). Chemotherapeutic drugs and ER stress inducers reduced cell number ( Figure 1B ) and growth ( Figure 1C ) in HT29 cells, but not in HT29/MDR cells (P = .04 at 48 hours; P = .006 at 72 hours) ( Figure 1, B and C) .
Comparison of basal, ER stress-induced, and chemotherapy-induced expression of the ER stress sensors ATF6, IRE1α, phospho(Ser724)IRE1α, PERK, phospho(Thr981)PERK, eIF2α, phospho(Ser51)eIF2α did not show any difference between HT29 and HT29/MDR cells ( Figure 2 ). Triggers of ER stress and chemotherapeutic agents induced CHOP/GADD153, TRB3, HERPUD1, cleaved caspase-3, and both C/EBP-β LAP and LIP in HT29 cells, with different kinetics ( Because Pgp transports chemotherapeutic drugs, but also toxins and xenobiotics (13) , it could potentially efflux thapsigargin, tunicamycin, and brefeldin A from HT29/MDR cells. Therefore, we examined the possible role of Pgp in the ER stress resistance phenotype of MDR cells. The Pgp inhibitor verapamil restored the intracellular accumulation of rhodamine 123 and doxorubicin in HT29/MDR cells (Supplementary Figure 3A, available online), but did not restore the toxicity of the ER stress inducers (Supplementary Figure 3B , available online), indicating that the increased activity of Pgp in HT29/MDR cells does not explain the resistance to ER stress-triggered cell death.
Thapsigargin, tunicamycin, and brefeldin A modulate ABC transporters activity and expression (15, (30) (31) (32) . Nevertheless, we found that in HT29 and HT29/MDR cells these agents did not change the efflux activity of Pgp, did not compete with rhodamine 123 for the efflux through Pgp, and did not change the expression of Pgp, MRP1, and MRP2 at the mRNA and protein levels ( Figure 2; Supplementary Figure 4 , available online). Hence, the increased resistance of HT29/MDR cells to ER stress was not because of increased efflux of these ER stress inducers, neither was it due to higher expression of Pgp. The same dual resistance to chemotherapeutic drugs and to ER stress inducers was observed also with A549/MDR cells, with the constitutively chemoresistant JC cells and with Caco-2 cells. For each cell type, we studied the chemotherapeutic agent that serves as first-line treatment choice of the respective tumor type. Importantly, each cell type exhibited a different C/EBP-β LIP/LAP ratio (data not shown).
C/EBP-β gene expression is regulated by many distinct transduction pathways, transcriptional inducers and repressors (33) . Such multiplicity of regulatory cues may explain the differences in C/EBP-β LAP expression levels in the different cell types. In contrast with C/EBP-β LAP, ER stress and chemotherapy did not trigger considerable induction of C/EBP-β LIP in the drugresistant cells. This behavior led us to hypothesize that the C/ EBP-β LIP/LAP ratio serves as a key mediator of the resistance to chemotherapy and to ER stress. mean ± SD = 91.8 ± 3.2%), 5-fluorouracil (cell survival: mean ± SD = 95.7 ± 3.3%) and oxaliplatin (cell survival: mean ± SD = 95.0 ± 2.5%), P ≤ .04 vs untransfected cells in all these experimental conditions ( Figure 3 , B and C, left panels). However, LAP overexpression did not affect the viability of drug-treated HT29/MDR cells (Supplementary Figure 5 , available online). In contrast, LIP overexpression sensitized HT29/MDR cells to brefeldin A (cell survival: mean ± SD = 54.7 ± 2.7%), irinotecan (cell survival: mean ± SD = 48.8 ± 2.1%), 5-fluorouracil (cell survival: mean ± SD = 56.0 ± 5.5%), and oxaliplatin (cell survival: mean ± SD = 53.4 ± 3.7%, P ≤ .04 vs untransfected cells in all these experimental conditions) ( Figure 3 , B and C, right panels). article as measured at 72 hours (Brefeldin A: mean ± SD = 95 000 ± 10 000 vs 235 000 ± 13 000, P = .001; irinotecan: mean ± SD = 85 000 ± 11 000 vs 247 000 ± 13 000 cells, P < .001; 5-fluorouracil: mean ± SD =116 000 ± 10 000 vs 240 000 ± 10 000 cells, P = .002; oxaliplatin: mean ± SD =136 000 ± 11 000 vs 257 000 ± 12 000 cells, P = .003) ( Figure 4C Transient overexpression of C/EBP-β LAP in HT29 cells elevated Pgp mRNA level by 3.54-fold (P < .001) ( Figure 5A ) and protein ( Figure 5C ), and increased the resistance to the Pgp substrates vinblastine (cell survival: mean ± SD = 87.0 ± 5.1% vs 61.2 ± 7.1%, P = .04) and etoposide (cell survival: mean ± SD = 81.2 ± 5.1% vs 43.1 ± 7.0%, P = .008) ( Figure 5D ). By contrast, transient or stable overexpression of C/EBP-β LIP in HT29/MDR cells downregulated Pgp mRNA levels by 4.2-and 4.73-fold (P < .001), respectively, ( Figure 5 , A and B), as well as Pgp protein ( Figure 5C ). Similar results were obtained with vinblastine (Transient LIP overexpression: mean ± SD = 52.8 ± 7.2 % vs 92.3 ± 7.2%, P = .02; inducible LIP overexpression: mean ± SD = 42.1 ± 3.4% vs 90.3 ± 5.3%, P = .004). These cells exhibited similar responses to etoposide as well (Transient LIP overexpression: mean ± SD = 41.2 ± 4.3% vs 91.3 ± 4.7%, P = .008; inducible LIP overexpression: mean ± SD = 43.0 ± 3.2% vs 89.1 ± 2.2%, P = .003) ( Figure 5D ).
Stable overexpression of LIP in the constitutively chemoresistant JC cells activated the CHOP/TRB3/capsase-3 axis in response to tunicamycin, doxorubicin, or paclitaxel, and also downregulated C/EBP-β LAP (Supplementary Figure 8A , available online). LIP overexpression decreased survival of tunicamycintreated JC cells (mean ± SD = 31.2 ± 2.2% vs 88.3 ± 4.3%, P = .002), of doxorubicin-treated cells (mean ± SD = 59.1 ± 4.2% vs 89.6 ± 3.3%, P = .01), and of paclitaxel-treated cells (mean ± SD = 46.3 ± 3.4% vs 81.7 ± 2.9%, P = .009) (Supplementary Figure 8 , B and C, available online). Similarly, LIP overexpression decreased the replication rate (measured at 72 hours) of tunicamycin-treated JC cells (mean ± SD = 46 000 ± 8 000 vs 334 000 ± 14 000 cells, P < .001), of doxorubicin-treated cells (mean ± SD = 107 000 ± 12 000 vs 367 000 ± 4 000 cells, P < .001, and of paclitaxel-treated cells (mean ± SD = 75 000 ± 14 000 vs 325 000 ± 10 000 cells, P < .001) (Supplementary Figure 8D, available online) . In parallel, LIP overexpression reduced Pgp expression by 34.0% (P = .04), and increased doxorubicin intracellular retention ( Supplementary  Figure 8 , E-G, available online).
To study the impact of C/EBP-β LIP on drug resistance in vivo, we orthotopically implanted JC TetON LIP cells in BALB/c mice, and treated them with vehicle or doxorubicin, with or without doxycycline in the drinking water. Doxorubicin alone had little effect on the tumor mass; induction of C/EBP-β LIP by doxycycline was sufficient to reduce tumor progression, and doxorubicin further reduced tumor size in mice receiving doxycycline (mean ± SD = 401 ± 137 mm 3 vs 1570 ± 167 mm 3 in untreated mice at day 15, P < .001) ( Figure 6, A and B) . Doxorubicin alone did not reduce statistically significantly the extent of cell proliferation and did not induce detectable signs of ER stress, as determined by immunostaining of Ki67 and HERPUD1, but upregulated Pgp in tumors, leading to drug resistance ( Figure 6, C and D) . Induction of C/EBP-β LIP reduced tumor cell proliferation and increased ER stress, without affecting Pgp levels. The extent of tumor cell proliferation in mice receiving both doxycycline and doxorubicin was similar to that of doxycycline alone, whereas the extent of ER stress was further increased as determined by the ER stress marker HERPUD1. Induction of Pgp by doxorubicin was reduced upon doxycycline-mediated induction of LIP, thereby providing one mechanism by which LIP might augment the cytotoxic activity of doxorubicin ( Figure 6 , C and D).
Post-Transcriptional Regulation of C/EBP-β LIP
We then investigated the molecular mechanisms underlying the lack of C/EBP-β LIP in chemotherapy-treated MDR cells. Sequencing of genomic C/EBP-β revealed that the chemosensitive HT29 cells and the chemoresistant HT29/MDR cells had identical DNA sequence in the ORF, 5'-UTR, 3'-UTR, and promoter regions (data not shown).
To check the stability of C/EBP-β mRNA or protein, we then treated HT29 and HT29/MDR cells with the transcription inhibitor actinomycin D, which time dependently decreased C/EBP-β mRNA, both in the absence or presence of irinotecan. C/EBP-β LAP protein also showed a progressive decrease, without appreciable differences between HT29 and HT29/MDR cells. LIP, which was induced by irinotecan in chemosensitive cells, progressively decreased in response to actinomycin D but was undetectable in HT29/MDR cells at all time points. A similar trend was observed in HT29 and HT29/MDR cells treated with the translation inhibitor cycloheximide. These results excluded that chemosensitive and chemoresistant cells differed in the stability of their C/EBP-β mRNA or protein (data not shown).
We found that the expression of ER quality control (ERQC) genes, often associated with increased protein ubiquitination (36), was attenuated in both HT29/MDR and A549/MDR cells (data not shown). Therefore, we compared the extent of C/ EBP-β LAP and LIP ubiquitination in chemosensitive vs MDR cells. Indeed, C/EBP-β LIP mono-ubiquitination was 3.56-fold higher in MDR cells compared with the chemosensitive cells (P < .001), whereas the same level of mono-ubiquitinated C/ EBP-β LAP was observed in these cells ( Figure 7A ). Inhibition of lysosomal degradation by leupeptin or ammonium chloride as well as inhibition of proteasomal degradation by MG132 prevented the disappearance of C/EBP-β LIP in the MDR cells ( Figure 7 , B and C, right panels). Irinotecan did not change the extent of C/EBP-β LIP mono-ubiquitination; however, it increased C/EBP-β LAP poly-ubiquitination ( Figure 7 , B and C, left panels). 
The impact of C/EBP-β LIP Degradation on the MDR Phenotype
To further study the role of C/EBP-β LIP in the MDR phenotype, we studied the impact of lysosomal and proteasomal inhibitors on Pgp expression and the cellular resistance to inducers of ER stress and to chemotherapy. Both NH 4 Cl and MG132 partially restored the cytotoxicity of the ER stress inducer brefeldin A in the ER stress-resistant HT29/MDR cells, and their combination resulted in full recovery of the cytotoxic response (survival: mean ± SD = 47.3 ± 4.7% vs 90.5 ± 4.5%, P = .02) ( Figure 7D ). In parallel, these inhibitors downregulated the basal level of Pgp mRNA by 3.7-fold (P < .001), as well as the Pgp protein level in the HT29/MDR cells ( Figure 7 , E and F). Similarly, these inhibitors restored the cytotoxic response of HT29/MDR cells to irinotecan (survival: mean ± SD = 55.4 ± 5.3% vs 93.1 ± 3.6%, P = .007) ( Figure 7G ).
The Role of C/EBP-β LIP in Resistance to ER Stress and Chemoresistance in Primary Tumors
To analyze the role of C/EBP-β LIP in primary resistant human tumors of different origin, we analyzed three samples of pleural malignant mesothelioma, three samples of glioblastoma multiforme, and three samples of chronic lymphocytic leukemia, chosen for their constitutively high levels of Pgp ( Figure 8A ). C/EBP-β LAP was expressed in all samples, whereas only low levels of C/ EBP-β LIP were found ( Figure 8A ). These cells were resistant to the ER stress inducer brefeldin A and to doxorubicin ( Figure 8B ). Furthermore, triggering of ER stress with brefeldin A did not induce C/EBP-β LIP in these cells ( Figure 8C ). Overexpression of C/EBP-β LIP downregulated Pgp ( Figure 8D ) and restored the cytotoxic efficacy of brefeldin A and doxorubicin (P = .003 and .004, respectively) ( Figure 8E ). A similar increase in C/EBP-β LIP reduced Pgp expression ( Figure 8D ) and increased response to brefeldin A; and doxorubicin was obtained by inhibiting proteasomal and lysosomal degradation using NH 4 Cl plus MG132 (P = .004 and P = .003, respectively) ( Figure 8E ).
Discussion
Tumor cell adaptation to ER stress requires activation of UPR-associated prosurvival mechanisms and attenuation of UPR-associated death-promoting mechanisms, such as those triggered by C/EBP-β LIP (2, 18) . LIP is necessary for promoting the nuclear translocation of CHOP (35), thereby activating the proapoptotic axis (4) . Earlier studies demonstrated that both chemotherapy and ER stress induce Pgp (13, 15, 16) and overexpression of C/EBP-β LIP lowers Pgp levels in MDR cells (19) . Our finding that MDR cells lack CHOP and cleaved caspase 3 suggest that continuous ER stress because of limited vasculature or chemotherapy selects for cells lacking C/EBP-β LIP. Our LIP complementation experiment suggests that loss of LIP drives the MDR phenotype by two mechanisms: It increases Pgp expression but also reduces ER stress-triggered cell death. Our findings show that the absence of C/EBP-β LIP rather than the C/EBP-β LIP/LAP ratio is a major trigger of the MDR phenotype. Interestingly, complementation of LIP not only restored the cytotoxic effects of Pgp substrates but also that of the MRP substrates 5-fluorouracil and oxaliplatin, which also induce ER stress (5, 7, 13, 26, 27, 29, 37) . Hence, LIP is probably involved in additional death-promoting mechanisms triggered by these MRP substrates. Several studies have previously shown that MDR cells are also resistant to the ER stress inducer thapsigargin. We found that these cells were also resistant to tunicamycin and brefeldin A, two ER stress inducers that are not Pgp substrates and in fact were reported to reverse the Pgp-mediated MDR (38, 39) . C/EBP-β LIP was recently shown to promote prosurvival mechanisms (40, 41) , however, these studies did not address its impact on the cellular response to ER stress or to chemotherapy.
C/EBP-β LIP is ubiquitinated and degraded by the proteasome in the early phase of the UPR, whereas it escapes degradation in the late phase (34, 35) . Mono-ubiquitinated proteins undergo lysosomal degradation (42) (43) (44) (45) , an event commonly taking place during late ER stress (46) . Hence, our finding that C/EBP-β LIP was subjected to higher basal mono-ubiquitination in HT29/ MDR cells as compared with HT29 cells provides a plausible mechanism driving its loss in MDR cells. Cathepsin L inhibitors were found to overcome resistance to tamoxifen, flutamide, doxorubicin, imatinib, and tricostatin by blocking lysosomal degradation of the respective target proteins (47) . In addition, it was suggested that ER stress renders cells more resistant to camptothecin and doxorubicin by increasing the degradation of topoisomerase I and II, an effect that was prevented by proteasome inhibitors (48) . Since doxorubicin, etoposide, imatinib, and the active metabolites of camptothecin and tamoxifen are effluxed by Pgp, our study provides an additional mechanism of MDR reversal based on the regulation of the Pgp level by cathepsin L inhibitors. C/EBP-β LAP and LIP were also poly-ubiquitinated to some extent, suggesting that their level is regulated both by lysosomal and proteasomal degradation.
Our findings were demonstrated using several resistant cell lines and three resistant primary tumor cells. Nevertheless, the reproducibility in several in vitro systems, which are accessible by other scientists, is not given; validation of our conclusions based on three samples per tumor entity can provide a trend at best.
In conclusion, we propose that loss of LIP by lysosomal and proteasomal degradation following its early ubiquitination drives the MDR by two independent mechanisms: upregulation of Pgp and attenuation of ER stress-triggered apoptosis. Because C/EBP-β LIP downregulates tumor progression (18) and improves the therapeutic benefits of Pgp substrates, preventing its lysosomal degradation may be an effective tool to overcome drug resistance. Our findings were demonstrated using several resistant cell lines and three resistant primary tumor cells. Nevertheless, the reproducibility in several in vitro systems, 
